EP Patent

EP2169071A1 — Rodent cancer model for human FGFR4 Arg388 polymorphism

Assigned to Max Planck Gesellschaft zur Foerderung der Wissenschaften eV · Expires 2010-03-31 · 16y expired

What this patent protects

The present invention provides a rodent animal for studying the molecular mechanisms and physiological processes associated with uncontrolled cell growth, e. g. cancer, and with a modified FGFR4.

USPTO Abstract

The present invention provides a rodent animal for studying the molecular mechanisms and physiological processes associated with uncontrolled cell growth, e. g. cancer, and with a modified FGFR4.

Drugs covered by this patent

Patent Metadata

Patent number
EP2169071A1
Jurisdiction
EP
Classification
—
Expires
2010-03-31
Drug substance claim
No
Drug product claim
No
Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.